Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK4.42 0.0  0.0%

Last Trade - 05/05/21

Sector
Industrials
Size
Small Cap
Market Cap £137.7m
Enterprise Value £126.4m
Revenue £2.70m
Position in Universe 826th / 1836

Annual General Meeting. Amended proposal for election to the Board of Directors.

Thu 8th April, 2021 9:53am
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210408:nGNE3GHHCG&default-theme=true


April 8, 2021
Announcement no. 7
 
 
Annual General Meeting. Amended proposal for election to the Board of
Directors.

The Board of Directors of BioPorto A/S has received notice that the board
members Torben Arnth Nielsen and Kirsten Aarup Drejer are not seeking
re-election. The Board of Directors consequently proposes the following
amended proposal for election of board members at the upcoming Annual General
Meeting:

The Board of Directors proposes re-election of the following current board
members: Thomas Magnussen (chairman), Christopher Lindop and Michael S.
Singer.

Further, the Board of Directors proposes election of Don M. Hardison, John
McDonough and Jan Leth Christensen as new members to the Board of Directors.

A description of the candidates (in both Danish and English) is attached to
this announcement.

Updated forms for providing proxy or voting by correspondence are available on
the Company’s website
http://bioporto.com/investor-relations/general-meetings and attached to this
announcement. Shareholders who may wish to amend a proxy already provided by
them may do so by contacting the Company (see below) or submitting a new proxy
via the shareholder portal
(https://bioporto.com/investor-relations/shareholder-portal/).

For further information, please contact:

Thomas Magnussen, Chairman of the Board

Telephone +45 4529 0000, e-mail: investor@bioporto.com

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies
to clinicians and researchers around the world. We use our antibody and assay
expertise to transform novel research tools into clinically actionable
biomarkers that can make a difference in patients’ lives. BioPorto is
headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen
stock exchange  CPH:BIOPOR .


Attachments
*     2021 04 08 - Company announcement no. 7
(https://ml-eu.globenewswire.com/Resource/Download/b9e8bbb7-3e02-495a-b59f-dbd0d790d275)
  
*     2021 04 08 - BioPorto - Updated CV
(https://ml-eu.globenewswire.com/Resource/Download/55b5ff78-96c0-4722-aefa-e44831770f45)
  
*     2021 04 08 - BioPorto - Opdateret CV
(https://ml-eu.globenewswire.com/Resource/Download/df008e4f-e9cd-4b8d-b351-c72d7f3d16f6)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.